Life Sciences Archives - Page 11 of 21 - Becker's Hospital Review

GLP-1 drugs in the works | Wegovy beats rival in trial | Walgreens to pay $106M over fraud allegations | Ozempic generics could cost 90% less

September 18, 2024 BHR Newsletter 1. Sanders: Ozempic generics could cost 90% less than brand-name Full story 2. GLP-1 weight loss pills are in the works: What to know Full story 3. Walgreens to pay $106.8M to settle billing fraud…

Eli Lilly value could hit $1T | AbbVie sues BeiGene over trade secret theft | AstraZeneca cancer drug fails trial | Trump-Harris debate: 3 healthcare takeaways

September 11, 2024 BHR Newsletter 1. AbbVie sues BeiGene over alleged trade secret theft Full story 2. 3 healthcare takeaways from the Trump-Harris debate Full story 3. Drugmaker might be 1st healthcare company to top $1 trillion valuation Full story…

Sandoz plans Ozempic generic US launch | Healthcare execs accused of lying to Congress | 6 drugs now in shortage | 10 healthcare industry lawsuits, settlements

September 4, 2024 BHR Newsletter 1. Lawmaker accuses CVS, Cigna, UnitedHealth execs of making false statements to Congress Full story 2. Sandoz plans 2030 US launch for Ozempic generic Full story 3. Wegovy, Ozempic users less likely to die from…

Pfizer goes direct to consumer | FDA clears new COVID shots | 4 updates on Mounjaro, Ozempic | CDC's outlook for 2024-25 virus season

August 28, 2024 BHR Newsletter 1. Pfizer goes direct to consumer Full story 2. CDC's outlook for 2024-25 virus season: 4 notes Full story 3. FDA clears new COVID shots: 3 notes Full story 4. Infusion wait times are down…

Eli Lilly takes action against copycats | Lyoks to lay off 75% of workforce | Patients tamper with Ozempic, Mounjaro | Walgreens inks $100M clinical trial deal

August 21, 2024 BHR Newsletter 1. Lykos to lay off 75% of workforce in wake of PTSD drug rejection Full story 2. FDA approves first-line treatment for lung cancer Full story 3. Eli Lilly takes action over Zepbound, Mounjaro copycats…

FDA calls out Bristol Myers | How 4 GLP-1 makers fared in Q2 | Medicare drug price negotiations: 10 notes | The GLP-1 questions facing health systems

August 14, 2024 BHR Newsletter 1. How GLP-1 makers fared in Q2 Full story 2. Medicare drug price negotiations: 10 things to know Full story 3. The GLP-1 questions facing health systems Full story 4. Learn how Northwestern Medicine and…

FDA OKs 1st gene therapy for synovial sarcoma | VP picks' stance on pharmaceutical costs | 42% of online semaglutide sellers are illegal | Drug combo could boost cancer treatment efficacy

August 7, 2024 BHR Newsletter 1. FDA approves 1st gene therapy for synovial sarcoma Full story 2. Where VP picks stand on pharmaceutical costs Full story 3. 42% of online pharmacies selling semaglutide are illegal: Study Full story 4. Labor…

Obesity pill trial earns drugmaker $16B | US drugmaker on verge of closure | 4 notes on fall COVID vaccines | Could Amazon be headed for big healthcare losses?

July 31, 2024 BHR Newsletter 1. Another US drugmaker on the verge of closure: Report Full story 2. 25-person obesity pill trial earns drugmaker $16.8B Full story 3. Could Amazon be headed for big healthcare losses? Full story 4. 1…

The state of drug shortages | The 'best' weight loss drug remains elusive | Endo recalls mislabeled drug lot | 10 top execs that have left Optum

July 24, 2024 BHR Newsletter 1. 'Best' weight loss drug remains elusive Full story 2. 10 top execs that have recently left Optum Full story 3. The state of drug shortages: ASHP Full story 4. 1 MD is 'democratizing expertise'…

Faux-zempic' market on the rise | Rite Aid hit with security breach | Cancer drug shortage: 8 updates | JD Vance's healthcare record: 7 things to know

July 17, 2024 BHR Newsletter 1. A rising market for 'faux-zempic' Full story 2. JD Vance's healthcare record: What hospital leaders should know Full story 3. Cancer drug shortage: 8 updates Full story 4. Streamline your clinical trial workflow and…